Subscribe to RSS
DOI: 10.1055/s-0031-1295725
Pneumocystis Pneumonia
Publication History
Publication Date:
13 December 2011 (online)

ABSTRACT
Pneumocystis (carinii) jiroveci pneumonia can occur in immunocompromised individuals, especially hematopoietic stem and solid organ transplant recipients and those receiving immunosuppressive agents, and is the most common opportunistic infection in persons with advanced human immunodeficiency virus (HIV) infection. The Pneumocystis genus was initially mistaken as a trypanosome and later as a protozoan. Genetic analysis identified the organism as a unicellular fungus. Pneumocystis jiroveci is the species responsible for human infections. A slow indolent time course with symptoms of pneumonia progressing over weeks to months is characteristic in HIV-infected patients. Fulminant respiratory failure associated with fever and dry cough is typical in non-HIV-infected patients. Definitive diagnosis relies on histopathological testing of sputum, induced or sampled by fiberoptic bronchoscopy with bronchoalveolar lavage. The first-line drug for treatment and prevention is trimethoprim-sulfamethoxazole.
KEYWORDS
Pneumocystis pneumonia - trimethoprim-sulfamethoxazole - Pneumocystis jiroveci
REFERENCES
- 1
Stringer J R, Beard C B, Miller R F, Wakefield A E.
A new name (Pneumocystis jiroveci) for Pneumocystis from humans.
Emerg Infect Dis.
2002;
8
(9)
891-896
Reference Ris Wihthout Link
- 2
Kovacs J A, Masur H.
Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis
and treatment.
JAMA.
2009;
301
(24)
2578-2585
Reference Ris Wihthout Link
- 3
Schmoldt S, Schuhegger R, Wendler T et al..
Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients
after kidney transplantation.
J Clin Microbiol.
2008;
46
(3)
966-971
Reference Ris Wihthout Link
- 4
de Boer M G, Bruijnesteijn van Coppenraet L E, Gaasbeek A et al..
An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal
transplant recipients: interhuman transmission or a common environmental source?.
Clin Infect Dis.
2007;
44
(9)
1143-1149
Reference Ris Wihthout Link
- 5
Sepkowitz K A.
Opportunistic infections in patients with and patients without acquired immunodeficiency
syndrome.
Clin Infect Dis.
2002;
34
(8)
1098-1107
Erratum in: Clin Infect Dis 2002 1:34(9):1293
Reference Ris Wihthout Link
- 6 Centers for Disease Control and Prevention (CDC). HIV/AIDS Surveillance Supplemental
Report, vol 9, no. 3. Atlanta, GA: Centers for Disease Control and Prevention; 2003: 1-20
Reference Ris Wihthout Link
- 7
Thomas Jr C F, Limper A H.
Pneumocystis pneumonia.
N Engl J Med.
2004;
350
(24)
2487-2498
Reference Ris Wihthout Link
- 8
Edman J C, Kovacs J A, Masur H, Santi D V, Elwood H J, Sogin M L.
Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi.
Nature.
1988;
334
(6182)
519-522
Reference Ris Wihthout Link
- 9
Cushion M T, Stringer J R.
Has the name really been changed? It has for most researchers.
Clin Infect Dis.
2005;
41
(12)
1756-1758
Reference Ris Wihthout Link
- 10
Gigliotti F.
Pneumocystis carinii: has the name really been changed?.
Clin Infect Dis.
2005;
41
(12)
1752-1755
Reference Ris Wihthout Link
- 11
Gigliotti F, Harmsen A G, Haidaris C G, Haidaris P J.
Pneumocystis carinii is not universally transmissible between mammalian species.
Infect Immun.
1993;
61
(7)
2886-2890
Reference Ris Wihthout Link
- 12
Ponce C A, Gallo M, Bustamante R, Vargas S L.
Pneumocystis colonization is highly prevalent in the autopsied lungs of the general
population.
Clin Infect Dis.
2010;
50
(3)
347-353
Reference Ris Wihthout Link
- 13
Morris A, Wei K, Afshar K, Huang L.
Epidemiology and clinical significance of pneumocystis colonization.
J Infect Dis.
2008;
197
(1)
10-17
Reference Ris Wihthout Link
- 14
Fischl M A, Dickinson G M, La Voie L.
Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis
carinii pneumonia in AIDS.
JAMA.
1988;
259
(8)
1185-1189
Reference Ris Wihthout Link
- 15
Walzer P D, Perl D P, Krogstad D J, Rawson P G, Schultz M G.
Pneumocystis carinii pneumonia in the United States: epidemiologic, diagnostic, and
clinical features.
Ann Intern Med.
1974;
80
(1)
83-93
Reference Ris Wihthout Link
- 16
Morris A, Lundgren J D, Masur H et al..
Current epidemiology of Pneumocystis pneumonia.
Emerg Infect Dis.
2004;
10
(10)
1713-1720
Reference Ris Wihthout Link
- 17
Murray J F.
Pulmonary complications of HIV-1 infection among adults living in Sub-Saharan Africa.
Int J Tuberc Lung Dis.
2005;
9
(8)
826-835
Reference Ris Wihthout Link
- 18
Yale S H, Limper A H.
Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome:
associated illness and prior corticosteroid therapy.
Mayo Clin Proc.
1996;
71
(1)
5-13
Reference Ris Wihthout Link
- 19
Bollée G, Sarfati C, Thiéry G et al..
Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients.
Chest.
2007;
132
(4)
1305-1310
Reference Ris Wihthout Link
- 20
Sepkowitz K A, Brown A E, Telzak E E, Gottlieb S, Armstrong D.
Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital.
JAMA.
1992;
267
(6)
832-837
Reference Ris Wihthout Link
- 21
De Castro N, Neuville S, Sarfati C et al..
Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation:
a 6-year retrospective study.
Bone Marrow Transplant.
2005;
36
(10)
879-883
Reference Ris Wihthout Link
- 22
Radisic M, Lattes R, Chapman J F et al..
Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a
case-control study.
Transpl Infect Dis.
2003;
5
(2)
84-93
Reference Ris Wihthout Link
- 23
Harigai M, Koike R, Miyasaka N. Pneumocystis Pneumonia under Anti-Tumor Necrosis Factor Therapy (PAT) Study Group .
Pneumocystis pneumonia associated with infliximab in Japan.
N Engl J Med.
2007;
357
(18)
1874-1876
Reference Ris Wihthout Link
- 24
Kaplan J E, Benson C, Holmes K H, Brooks J T, Pau A, Masur H. Centers for Disease Control and Prevention (CDC) .
Guidelines for prevention and treatment of opportunistic infections among HIV-infected
adults and adolescents: recommendations from CDC, the National Institutes of Health,
and the HIV Medicine Association of the Infectious Diseases Society of America.
MMWR Recomm Rep.
2009;
58
(RR-4)
1-207, quiz CE1–CE4
Reference Ris Wihthout Link
- 25
Shelburne III S A, Hamill R J, Rodriguez-Barradas M C et al..
Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during
highly active antiretroviral therapy.
Medicine (Baltimore).
2002;
81
(3)
213-227
Reference Ris Wihthout Link
- 26
French M A, Lenzo N, John M et al..
Immune restoration disease after the treatment of immunodeficient HIV-infected patients
with highly active antiretroviral therapy.
HIV Med.
2000;
1
(2)
107-115
Reference Ris Wihthout Link
- 27
Stover D E, Greeno R A, Gagliardi A J.
The use of a simple exercise test for the diagnosis of Pneumocystis carinii pneumonia
in patients with AIDS.
Am Rev Respir Dis.
1989;
139
(6)
1343-1346
Reference Ris Wihthout Link
- 28
Boiselle P M, Crans Jr C A, Kaplan M A.
The changing face of Pneumocystis carinii pneumonia in AIDS patients.
AJR Am J Roentgenol.
1999;
172
(5)
1301-1309
Reference Ris Wihthout Link
- 29
Gruden J F, Huang L, Turner J et al..
High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii
pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings.
AJR Am J Roentgenol.
1997;
169
(4)
967-975
Reference Ris Wihthout Link
- 30
Coleman D L, Hattner R S, Luce J M, Dodek P M, Golden J A, Murray J F.
Correlation between gallium lung scans and fiberoptic bronchoscopy in patients with
suspected Pneumocystis carinii pneumonia and the acquired immune deficiency syndrome.
Am Rev Respir Dis.
1984;
130
(6)
1166-1169
Reference Ris Wihthout Link
- 31
Raviglione M C.
Extrapulmonary pneumocystosis: the first 50 cases.
Rev Infect Dis.
1990;
12
(6)
1127-1138
Reference Ris Wihthout Link
- 32
Shelhamer J H, Gill V J, Quinn T C et al..
The laboratory evaluation of opportunistic pulmonary infections.
Ann Intern Med.
1996;
124
(6)
585-599
Reference Ris Wihthout Link
- 33
Bigby T D.
Diagnosis of Pneumocystis carinii pneumonia. How invasive?.
Chest.
1994;
105
(3)
650-652
Reference Ris Wihthout Link
- 34
Broaddus C, Dake M D, Stulbarg M S et al..
Bronchoalveolar lavage and transbronchial biopsy for the diagnosis of pulmonary infections
in the acquired immunodeficiency syndrome.
Ann Intern Med.
1985;
102
(6)
747-752
Reference Ris Wihthout Link
- 35
Armbruster C, Pokieser L, Hassl A.
Diagnosis of Pneumocystis carinii pneumonia by bronchoalveolar lavage in AIDS patients:
comparison of Diff-Quik, fungifluor stain, direct immunofluorescence test and polymerase
chain reaction.
Acta Cytol.
1995;
39
(6)
1089-1093
Reference Ris Wihthout Link
- 36
Kovacs J A, Ng V L, Masur H et al..
Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use
of monoclonal antibodies.
N Engl J Med.
1988;
318
(10)
589-593
Reference Ris Wihthout Link
- 37
Wakefield A E, Guiver L, Miller R F, Hopkin J M.
DNA amplification on induced sputum samples for diagnosis of Pneumocystis carinii
pneumonia.
Lancet.
1991;
337
(8754)
1378-1379
Reference Ris Wihthout Link
- 38
Larsen H H, Masur H, Kovacs J A et al..
Development and evaluation of a quantitative, touch-down, real-time PCR assay for
diagnosing Pneumocystis carinii pneumonia.
J Clin Microbiol.
2002;
40
(2)
490-494
Reference Ris Wihthout Link
- 39
Azoulay E, Bergeron A, Chevret S, Bele N, Schlemmer B, Menotti J.
Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immunocompromised
patients with pulmonary infiltrates.
Chest.
2009;
135
(3)
655-661
Reference Ris Wihthout Link
- 40
Boldt M J, Bai T R.
Utility of lactate dehydrogenase vs radiographic severity in the differential diagnosis
of Pneumocystis carinii pneumonia.
Chest.
1997;
111
(5)
1187-1192
Reference Ris Wihthout Link
- 41
Desmet S, Van Wijngaerden E, Maertens J et al..
Serum (1-3)-beta-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia
in patients with human immunodeficiency virus infection or hematological malignancy.
J Clin Microbiol.
2009;
47
(12)
3871-3874
Reference Ris Wihthout Link
- 42
Safrin S, Finkelstein D M, Feinberg J et al..
Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii
pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole,
dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group.
Ann Intern Med.
1996;
124
(9)
792-802
Reference Ris Wihthout Link
- 43
Kovacs J A, Gill V J, Meshnick S, Masur H.
New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii
pneumonia.
JAMA.
2001;
286
(19)
2450-2460
Reference Ris Wihthout Link
- 44
Fishman J A.
Treatment of infection due to Pneumocystis carinii.
Antimicrob Agents Chemother.
1998;
42
(6)
1309-1314
Reference Ris Wihthout Link
- 45
Noskin G A, Murphy R L, Black J R, Phair J P.
Salvage therapy with clindamycin/primaquine for Pneumocystis carinii pneumonia.
Clin Infect Dis.
1992;
14
(1)
183-188
Reference Ris Wihthout Link
- 46
Smego Jr R A, Nagar S, Maloba B, Popara M.
A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia.
Arch Intern Med.
2001;
161
(12)
1529-1533
Reference Ris Wihthout Link
- 47
Queener S F, Bartlett M S, Richardson J D, Durkin M M, Jay M A, Smith J W.
Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and
in vivo.
Antimicrob Agents Chemother.
1988;
32
(6)
807-813
Reference Ris Wihthout Link
- 48
Helweg-Larsen J, Benfield T, Atzori C, Miller R F.
Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis
jirovecii pneumonia: a tri-centre cohort study.
J Antimicrob Chemother.
2009;
64
(6)
1282-1290
Reference Ris Wihthout Link
- 49
Medina I, Mills J, Leoung G et al..
Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome:
a controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone.
N Engl J Med.
1990;
323
(12)
776-782
Reference Ris Wihthout Link
- 50 Walzer P D, Smulian G A. Pneumocystis species. In: Mandell G L, Bennett J E, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th
ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2010: 3385
Reference Ris Wihthout Link
- 51
Klein N C, Duncanson F P, Lenox T H et al..
Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia
in AIDS patients: results of a large prospective randomized treatment trial.
AIDS.
1992;
6
(3)
301-305
Reference Ris Wihthout Link
- 52
Bozzette S A.
The use of corticosteroids in Pneumocystis carinii pneumonia.
J Infect Dis.
1990;
162
(6)
1365-1369
Reference Ris Wihthout Link
- 53
Bozzette S A, Sattler F R, Chiu J California Collaborative Treatment Group et al.
A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis
carinii pneumonia in the acquired immunodeficiency syndrome.
N Engl J Med.
1990;
323
(21)
1451-1457
Reference Ris Wihthout Link
- 54 Wagner K R, Chaisson R E. Pulmonary complications of HIV infection. In: Wormser G P, ed. AIDS and Other Manifestations of HIV Infection. 4th ed. Milan, Italy: Elsevier Academic; 2004: 411
Reference Ris Wihthout Link
- 55
Helweg-Larsen J, Benfield T L, Eugen-Olsen J, Lundgren J D, Lundgren B.
Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome
of AIDS-associated P. carinii pneumonia.
Lancet.
1999;
354
(9187)
1347-1351
Reference Ris Wihthout Link
- 56
Takahashi T, Hosoya N, Endo T et al..
Relationship between mutations in dihydropteroate synthase of Pneumocystis carinii
f. sp. hominis isolates in Japan and resistance to sulfonamide therapy.
J Clin Microbiol.
2000;
38
(9)
3161-3164
Reference Ris Wihthout Link
- 57
Nahimana A, Rabodonirina M, Helweg-Larsen J et al..
Sulfa resistance and dihydropteroate synthase mutants in recurrent Pneumocystis carinii
pneumonia.
Emerg Infect Dis.
2003;
9
(7)
864-867
Reference Ris Wihthout Link
- 58
Huang L, Crothers K, Atzori C et al..
Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance.
Emerg Infect Dis.
2004;
10
(10)
1721-1728
Reference Ris Wihthout Link
- 59
Navin T R, Beard C B, Huang L et al..
Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome
of P carinii pneumonia in patients with HIV-1: a prospective study.
Lancet.
2001;
358
(9281)
545-549
Reference Ris Wihthout Link
- 60
Green H, Paul M, Vidal L, Leibovici L.
Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.
Cochrane Database Syst Rev.
2007;
(3)
CD005590. doi:10.1002/14651858.CD005590
Reference Ris Wihthout Link
- 61
Sepkowitz K A.
Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: who should
receive prophylaxis?.
Mayo Clin Proc.
1996;
71
(1)
102-103
Reference Ris Wihthout Link
- 62
Velayos F S, Sandborn W J.
Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha
therapy with infliximab for Crohn’s disease.
Inflamm Bowel Dis.
2004;
10
(5)
657-660
Reference Ris Wihthout Link
Shelley A. GilroyM.D.
Division of Infectious Disease/HIV Medicine, Albany Medical College
47 New Scotland Ave. MC 158, Albany, NY 12208
Email: gilroys@mail.amc.edu